MSD, Samsung's Glargine Biosimilar Hits Phase III Endpoints
This article was originally published in PharmAsia News
MSD has unveiled positive new results from two Phase III clinical trials with its investigational insulin glargine biosimilar, and the progress is set to further accelerate the commercialization of the diverse biosimilar pipeline at partner Samsung Bioepis, which is partially funding development of the product.
You may also be interested in...
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
With multiple South Korean INDs to begin Phase III trials with its SGLT-2 inhibitor enavogliflozin, Daewoong is aiming to speed domestic and global development of the potentially best-in-class drug for type 2 diabetes.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.